We systematically screened for the aetiology of thrombophilia in 115 patients with venous, arterial and small vessel thromboses. Forty-one patients (36% of those we examined) suffering from a variety of thromboses, including deep vein thrombosis, pulmonary embolism, arterial occlusion, cerebral infarction, Moyamoya disease and ulcerative colitis, were characterized either with positive lupus anticoagulants or with decreased activities of protein S, protein C, antithrombin III and/or plasminogen. Eight mutation sites were confirmed in 11 thrombotic patients using gene analysis.
INTRODUCTION
Thrombophilia is defined as an increased tendency to thrombosis.v' and can be either inherited or acquired. Thrombus formation is regulated by the anticoagulatory and fibrinolytic systems in the vascular endothelial cells. 4 ,5 Thrombophilia has been shown to be caused by molecular abnormalities of antithrombin III (AT III), protein C (PC) and protein S (PS) as well as by activated protein C (APC) resistance due to mutation in the factor V molecule.I! Association with thrombophilia has yet to be established definitely for inherited abnormalities of the plasminogen molecule, dysfibrinogenaemia, heparin cofactor II abnormality, increase in histidine-rich glycoprotein and decrease in plasminogen activator activity. Venous thrombosis is the most common clinical manifestation of such thrombophilia. The prevalence of inherited AT III, PC and PS abnormalities in patients with venous thrombosis has been reported to be approximately 5_10%.3.6.7 APC resistance shows racial specificity, being observed at high frequency (20-50%) in Caucasian patients with venous thrombosis't'' but rarely in the Japanese and other Eastern populations. 10 ,1 1 Antiphospholipid syndrome is an acquired thrombophilia in which antibodies, including lupus anticoagulants (LA) and anticardiolipin antibodies, have been proven to be associated with thrombosis, recurrent foetal loss and thrombocytopenia.Fi'! Thrombophilia may also result from other acquired disorders, such as malignancy, myeloproliferative disorders and nephrotic syndrome, although the mechanism of thrombosis remains to be clarified. ' Aetiological investigation is a prerequisite for the treatment and prevention of multifactorial diseases such as thrombophilia. In this study, we established a screening programme for the aetiology of thrombophilia in 115 patients with venous, arterial or small vessel thromboses.
MATERIALS AND METHODS

Samples
Venous blood samples (9 mL) were collected in 1mL of 3·2% (0'105mol/L) sodium citrate and platelet-poor plasma was prepared by centrifugation at 1500g for lOmin at 4°C. Leucocytes were obtained from the cell pellet by sedimentation in 1·5% dextran followed by haemolysis and genomic DNA was extracted using the Sepa Gene kit (Sanko Junyaku, Tokyo, Japan) and stored at 4°C and -80°C. The plasma was either freshly prepared each time or stored in small aliquots at -80°C.
Strategy for the systematic examination of thrombophilia The scheme used for the evaluation of thrombophilia is shown in Fig. I . Thrombus formation was first assessed by clinical history and then confirmed by imaging analyses including computerized tomography, magnetic resonance imaging, scintillation analysis and angiography. All analyses were done either before anticoagulant Marburg, Germany). Concentrations of PC and PS were measured by enzyme-linked immunosorbent assay (ELISA) (Asserachrom Protein C and Asserachrom Protein S, respectively, Diagnostica Stago). Free PS was measured after removing the PS/C4BP complex from plasma by polyethylene glycol-precipitation.P The distribution of free and complexed forms of PS in plasma was analysed by crossed immunoelectrophoresis using a rabbit anti-human PS antibody according to the method of Comp et al. 15 C4BP was measured by a single radial immunodiffusion method using a rabbit polyclonal antibody donated by Dr Fujita (Fukushima Medical College, Japan). Lupus anticoagulants were detected by a diluted activated partial thromboplastin time (APTT) method!" using a sixfold-diluted APTT reagent (Automated APTT, Organon Teknika Co). The criteria for the presence of LA are: (a) the clotting time of the patient's plasma is more than 5 s longer than that of the I: I mixture of patient's plasma with the pooled normal plasma, and (b) the clotting time of patient's plasma measured with diluted reagent is prolonged more than 1·22 times that measured with nondiluted reagent. These values were determined as 3 SD above the mean of the data obtained from 58 healthy volunteers.
Clinical assessment of thrombosis
Protein S was purified from human plasma according to the method of Dahlback et al. 17 Antiserum against human PS was obtained by immunizing rabbits with the purified protein.
Gene analysis
Each of the exons and adjacent intron/exon boundaries of the PS (exons 1_15),18-20 AT III (exons 1--6),21 PC (exons 1_9)22 and plasminogen (exon 15)23 genes were amplified by the polymerase chain reaction (PCR)24 using a Gene-Amp PCR system 9600-R (Perkin Elmer, Norwalk, USA). Due to the presence of an inactive PS pseudogene (PSP gene) adjacent to the active PS gene (PSrx gene),25 primers were designed from genomic sequences for the specific amplification of the PSrx gene (allele-specific PCR). Single-strand conformation polymorphism analysis for amplified fragments was performed using a PhastSystem™ (Pharmacia Biotech AB, Uppsala, Sweden) as described by Orita et al. 26 After purification of PCR fragments with MicroSpin S-300 HR columns (Pharmacia Biotech AB), direct DNA sequencing was performed according to the dideoxy Ann Clin Biochem 1999: 36 chain termination method-? using an ABI PRISM™ 377 DNA Sequencer (Perkin-Elmer Applied Biosystems, Foster CA, USA). Some amplified fragments were subcloned into the sequencing vector, pCR™ II (Invitrogen, San Diego CA, USA), and DNA sequencing was performed on at least ten clones. To confirm the mutation, restriction fragment length polymorphism analysis was carried out on the amplified DNA fragments.
RESULTS AND DISCUSSION
Clinical features of patients examined Between June 1993 and June 1996, 133 Japanese patients (68 men, 65 women) were studied and 18 patients were excluded by the initial clinical assessment of thrombosis and the basic laboratory tests, leaving 115 patients (59 men, 56 women) in the investigation. The clinical manifestations in these patients are summarized in Table 2 . The latest episode of thrombosis was categorized as venous (38 patients, 33% of total), arterial (58 patients, 50%), or small vessel (19 patients, 17%) (see Table 2 ).
Aberrant factors found in patients
Aberrant factors recognized in patients are shown in Table 2 . A high incidence of decreased PS anticoagulant activity was found (23 out of 115 examined patients, 20%). AT III heparin cofactor activity, PC anticoagulant activity and plasminogen activity were decreased in three patients (3%), six patients (5%) and four patients (4%), respectively. LA was detected in ten patients (9%). No case of abnormal levels of fibrinogen or reduced heparin cofactor II activity was detected in the patients examined. Five patients showed two coincident abnormalities: two had low PS and LA positivity, two had low PS and low PC activities and one had low PS and low plasminogen activity. In total, 41 patients (36% of the examined cases) showed one or more abnormalities. These patients suffered not only from venous thrombosis but also from arterial and small vessel thrombosis (see Table 2 ). LA-positive patients were predisposed to arterial thrombosis conditions such as cerebral infarction and chronic arterial occlusion (see Table 2 ). Table 3 shows the clinical details, free PS, total PS and C4BP concentrations in the 23 patients Table 3 ). The frequency ofarterial thrombosis due to low PS activity (12%) was lower than that of venous (29%) and small vessel thrombosis (26%) (see Table 2 ). This frequency is much higher than that previously published (5_10%),3,6,7,28 suggesting the important role of PS in the pathogenesis of thrombosis in the Japanese population.
Patients with decreased PS activity
Only 3 of the 23 patients with low PS activity had low total PS concentration (see Table 3 ), thus emphasizing the importance of measuring PS activity. In all patients except case 8, free PS was almost proportional to the PS activity. In case 8, free PS was 115% but the PS activity was 35%, suggesting that this patient has either an abnormal PS molecule or an inhibitor(s) of PS. No anti-PS antibody was detected in the serum samples from any of the 23 patients (data not shown), and the C4BP concentration was normal or nearly normal in all patients. Family studies performed on ten patients (cases 1, 2, 3, 5, 8, 10, 12, 13, 16 and 18) revealed that the firstdegree relatives offour patients (cases 1,2,5 and 8) had low levels of PS activity. None of these family members with decreased PS activity had yet suffered from an episode of thrombosis.
Patients with decreased AT III activity
Heparin cofactor activity of AT III was decreased in three patients (cases 24-26) (see Table 4a ). Case 26, a 4-year-old child with a rapidly progressing nephrotic syndrome, suffered from multiple cerebral infarctions when 's disease  35  58  92  147  21  19  17  F  DC  36  63  74  93  22  50  30  F  DC  47  57  85  84  23  25 her AT III activity as well as its concentration fell to~30%, in spite of repetitive administration of AT III compound. Fortunately, she recovered with prednisolone treatment and her AT III activity and concentration returned to normal. Decreased AT III in nephrotic syndrome appears to be a consequence of both urinary loss and consumption by accelerated intravascular coagulation.Y'" Case 24 had a low AT III activity with a low concentration of AT III, while case 25 had a low AT III activity with a normal AT III concentration (see Table 4a ). Progressive antithrombin activity measured in the absence of heparin was also decreased in case 25, suggesting that the decrease in the patient's AT III level could be ascribed to active site defects." The patient was found to be a heterozygote for an abnormal AT III with a deletion of Gly3S1 located near the Ann Clin Biochem 1999: 36 reactive site (Arg393_Ser394) (unpublished observations). A family study revealed that case 24 had a sister with low AT III activity.
Patients with decreased PC activity Persistently decreased PC activity was observed in six patients, and four of these had Moyamoya disease (see Table 4b ). One other patient suffering from the disease had low PS activity (see Table 2 ). Moyamoya disease is a clinical entity of unknown aetiology and is characterized by angiographic findings of bilateral occlusion at the terminal portion of the internal carotid artery together with a vascular network at the base of the brain. 32 Although the causal relationship between the disease and the anticoagulant pathway of the PC/PS system remains to be examined, the PC/PS system might be related to its pathogenesis. No. = number.
Patients with decreased plasminogen activity Decreased plasminogen activity was found in four patients (see Table 4c ). In case 22, a decrease in PS activity was also observed (see Table 3 ). All four patients had normal plasminogen concentrations (see Table 4c ), suggesting the molecule was aberrant. All cases were heterozygous for a gene substitution (Ala 60 I -Thr) (unpublished observations). The gene frequency of plasminogen abnormality associated with this mutation is relatively high in the Japanese population (0'02)33.34 and is comparable to that of previous reports.Pr"
LA-positive patients Arterial thrombosis was a dominant clinical manifestation in LA-positive patients (see Table  4d ). Venous thrombosis as well as small vessel thrombosis also occurred in LA-positive patients (see Table 4d ). This implies that arterial, venous and small vessel thrombosis are associated with the LA-positive condition, as previously suggested.P'!' Four patients were associated with autoimmune diseases such as SLE (cases 36, 39 and 40) and Evans' syndrome (case 41). Two LA-positive patients (cases 16 and 17) had low PS activities. It should be noted that certain subgroups of patients with antiphospholipid syndrome have been reported to have a high prevalence of free PS deficiency"
Gene analyses Table 5 shows the results of the gene analysis in the 33 patients in whom the analysis was done. Eight mutations in 11 patients were uncovered by gene analyses. At present, no high frequency mutations have been identified except for the abnormal plasminogen molecule of (Ala 60 I -Thr) substitution. This may be related, at least in part, to a predisposition for thrornbosis.P Ann Clin Biochem 1999: 36
CONCLUSION
Approximately 40% of the patients suffering from thrombosis had some defect in the regulatory system of blood coagulation. Decreased PS activity was found at high incidence in patients suffering not only from venous thrombosis but also from arterial and small vessel thrombosis. This indicates that the decreased activity of any factor in the regulatory system of coagulation, i.e., AT III, PS, PC or plasminogen, could be an aetiological cause inducing thrombosis, irrespective of whether the aberration was inherited or acquired. We conclude that the screening system for AT III, PC, PS, fibrinogen, heparin cofactor II, plasminogen and LA was useful for aetiological analyses of patients suffering from thrombosis.
